CN Stock MarketDetailed Quotes

600276 Jiangsu Hengrui Pharmaceuticals

Watchlist
  • 48.75
  • +0.07+0.14%
Market Closed Nov 6 15:00 CST
310.98BMarket Cap57.08P/E (TTM)

Jiangsu Hengrui Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Jiangsu Hengrui Pharmaceuticals Q3 2024 Earnings Date

Currency：CNYOct 25, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
6.73B
6.59B
-145.67M
Miss Est.
+15.21%
+12.72%
-2.16%
Net Income
--
1.19B
--
+2.38%
Analyst Rating
Strong Buy

Nov 6, 2024

Jiangsu Hengrui Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CNY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 6.572B--
--2024/Q4-- / 7.088B--
Oct 25, 20242024/Q36.589B / 6.734B--
Aug 22, 20242024/Q27.603B / 6.648B--
Apr 18, 20242024/Q15.998B / 6.071B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 6.572B--
--2024/Q4-- / 7.088B--
Oct 25, 20242024/Q36.589B / 6.734B--
Aug 22, 20242024/Q27.603B / 6.648B--
Apr 18, 20242024/Q15.998B / 6.071B--

Unlock Free Earnings Estimates

Jiangsu Hengrui Pharmaceuticals Earnings Reports

  • Hengrui Pharmaceutical Report for the Third Quarter of 2024

    Oct 24 12:00 ET

  • Jiangsu Hengrui Pharmaceuticals Semi-Annual Report for 2024

    Aug 21 12:00 ET

  • Jiangsu Hengrui Pharmaceuticals 2024 Interim Report Summary

    Aug 21 12:00 ET

  • Summary of Hengrui Pharmaceutical's 2023 Annual Report

    Apr 17 12:00 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 6, 2024

    Strong Buy

    • Strong Buy

      89.19%

    • Buy

      8.11%

    • Hold

      2.70%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    CN
    Overall
    Symbol
    Latest Price
    % Chg

    No Data